Skip to main content

Table 1 Characteristics of the TA patients and HCs

From: Chromogranin-A production and fragmentation in patients with Takayasu arteritis

  HCs TA (N = 42) p value
Qualitative variables
 Sex (F:M) 20:0 39:3 n.s.
 Class of arterial involvement: N.E.   
  1
  2A
  2B
  3
  4
  5
-
-
-
-
-
-
4 (10 %)
4 (10 %)
3 (7 %)
1 (2 %)
0
30 (71 %)
-
-
-
-
-
-
 Coronary involvement N.E. 6 (14 %) -
 Pulmonary artery involvement N.E. 13 (31 %) -
 Aneurysms 0 16 (38 %) -
 Steroids 0 30 (71 %) -
 Immunosuppressive therapy:
  Azathioprine
  Methotrexate
  Mycophenolate
  Sirolimus
  Cyclophosphamide
0
-
-
-
-
-
30 (71 %)
12 (29 %)
11 (26 %)
4 (10 %)
2 (5 %)
1 (2 %)
-
-
-
-
-
-
 Biologic therapy:
  TNF blockers
  Tocilizumab
  Rituximab
0
-
-
-
19 (45 %)
16 (38 %)
2 (5 %)
1 (2 %)
-
-
-
-
 Active disease (NIH criteria) N.E. 12 (29 %) -
 Anticoagulants 0 7 (17 %) -
 Arterial hypertension 0 22 (52 %) -
 Cardiac involvement N.E. 12 (29 %) -
 Vascular enhancement (N = 30) N.E. 5 (16 %) -
 Vascular progression (N = 40) N.E. 9 (22 %) -
Scalar variables (median, range)
 Age at disease onset (years) N.E. 30 (17–56) -
 Disease duration (years) N.E. 10 (0-34) -
 Creatinine (mg/dl) N.A. 0.70 (0.44–1.60) -
 PDN dose (mg/day; N = 30) 0 5 (3–35) -
 N vessels N.E. 4 (1–7) -
 ESR (mm/h) N.A. 15 (1–78) -
 Serum CRP (mg/l) 0.6 (0.3–9.0) 2.6 (0.03–40) 0.017
 Plasma PTX3 (ng/ml) 3.9 (1.4–6.5) 5.5 (1.3–55) 0.009
 CgAtot (nM) 0.98 (0.47–1.72) 2.36 (0.45–7.85) 0.001
 CgA439 (nM) 0.04 (0–0.07) 0.05 (0-0–.78) n.s.
 CgA-FRs (nM) 0.64 (0.22–1.17) 1.63 (0.22–6.68) 0.001
 VS-1 (nM) 0.10 (0.07–0.50) 0.20 (0.02–1.15) 0.020
 CgA439/CgAtot 5 % (0–17 %) 1 % (0–24 %) n.s.
 CgA-FRs/CgAtot 67 % (46–88 %) 66 % (47–94 %) n.s.
 VS-1/CgAtot 13 % (7–29 %) 11 % (1–27 %) n.s.
  1. Quantitative and qualitative variables related to TA were evaluated in TA patients and healthy controls (HCs). N vessels refers to the number of vessels involved by the disease (see “Methods”)
  2. TA Takayasu arteritis, n.s. not significant, TNF tumour necrosis factor, N.E. not evaluable, N.A. not available, PDN prednisone, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PTX3 pentraxin-3, CgA tot total chromogranin-A, CgA 439 full-length CgA (residues 1–439), CgA-FRs fragments of CgA spanning from the N-terminus to the central region but lacking the C-terminal region, VS-1 vasostatin-1